Measure 410
Psoriasis: Clinical Response to Systemic Medications
DESCRIPTION:
The percentage of psoriasis vulgaris patients receiving systemic medication who meet minimal physician- or patient-reported disease activity levels.
| MEASURE ID: | 410 |
|---|---|
| Type: | Outcome |
CMS Derm Specialty Set: | Yes |
| High priority: | Yes |
| Topped out: | No |
| Telehealth Eligible: | Yes |
| Reporting methods: | Registry/QCDR |
| Maximum points: | 10 |
MEASURE PURPOSE:
A significant proportion of psoriasis patients who are receiving treatment remain unsatisfied with their therapies, and treatment dissatisfaction can lead to patients discontinuing their medication. This measure evaluates the proportion of psoriasis vulgaris patients receiving systemic medication who meet minimal physician- or patient-reported disease activity levels to increase patient satisfaction and adherence to treatment.
Measure 410 FAQs
Q. Is this measure reportable via claims?
A. No.
Q. Are patient encounters conducted via telehealth allowable?
A. Yes, encounters coded with GQ, GT, or POS 02 modifiers are allowable.
Q. Does this measure need to be reported every time the patient comes into the office?
A. No, this measure only needs to be reported once per performance period.
Q. Why is a static benchmark used rather than PASI 75 or PASI 90?
A. The measure is evaluating whether a specific level of clearance is achieved rather than improvement over time.
Q. What medications are applicable to the measure?
A. Applicable medications can be found in the measure specification located on this page.
Q. Can I report on this measure if I did not prescribe the medication?
A. No, only the provider who prescribes the medication is eligible for this measure.
Q. Is this measure reportable for all types of psoriasis?
A. No, this measure is only reportable for psoriasis vulgaris (plaque psoriasis).
Q. For measures 410, is there a minimum number of patients required to report?
A. You should report all applicable cases across all payers. Requirements include a minimum of 20-cases. If you are a small practice (composed of no more than 15 providers) 75% of the data should be complete to earn more than the 3-point minimum.
Q. Can I add a calculation of Body Surface Area (BSA) in the note based on other information?
A. If the involvement is diagrammed where an accurate BSA can be calculated, then yes, this calculation can be recorded in the medical record.
Assessment tools are below.
Physician global assessment (PGA)
Calculation
The numerator: Patients who have a documented physician global assessment (PGA; 5-point OR 6-point scale), body surface area (BSA), psoriasis area and severity index (PASI) and/or dermatology life quality index (DLQI) that meet any one of the specified benchmarks:
- PGA (5-point OR 6-point scale) ≤ 2 (clear to mild skin disease)
- BSA < 3% (mild disease)
- PASI < 3 (no or minimal disease)
- DLQI ≤ 5 (no effect or small effect on patient’s quality of life)
The denominator: All patients with a diagnosis of psoriasis vulgaris who are treated with a systemic medication.
Measure calculation example
Dr. Chen saw 47 patients who have a diagnosis of psoriasis vulgaris and receive systematic medications during the reporting period. This is the denominator. Of the 47 patients, 31 have a documented physician global assessment, BSA, PASI, and/or DLQI that meet one of the specified benchmarks. This is the numerator.
Quality of patient care = 31/47. Dr. Chen has a score of 66% for this measure. This translates to 2.0 to 2.9 points.
Important note
Because of how this measure is structured, physicians score 3 points even if they report on only one patient. This is applicable only to small practices with 15 providers or fewer.
Quality measure score benchmark
CMS will award points based on a comparison of your performance rate to CMS benchmarks listed below. Reach the performance rate listed to achieve the corresponding points per measure. Points achieved for the Quality category will account for 30% of the overall MIPS score.
| Decile 1 | Decile 2 | Decile 3 | Decile 4 | Decile 5 | Decile 6 | Decile 7 | Decile 8 | Decile 9 | Decile 10 |
|---|---|---|---|---|---|---|---|---|---|---|
Performance rate |
9.68 - 55.12 |
55.13 - 77.13 |
77.14 - 90.35 |
90.36 - 96.54 |
96.55 - 99.99 |
-- |
-- |
-- |
-- |
100 |
Points |
1.0 - 1.9 |
2.0 - 2.9 |
3.0 - 3.9 |
4.0 - 4.9 |
5.0 - 5.9 |
-- |
-- |
-- |
-- |
10 |
Training on psoriasis assessment tools
The American Academy of Dermatology and the Group for Research and Assessment for Psoriasis and Psoriatic Arthritis (GRAPPA) collaborated to provide free short educational videos on how to use psoriasis assessment tools.
Introduction
Introduction to psoriasis assessment tools for MIPS #410 ( 3:55 minutes)
PASI
Psoriasis Area and Severity Index (PASI) (10:59 minutes)
